Compare Sun Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs TORRENT PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA TORRENT PHARMA SUN PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 27.6 38.6 71.5% View Chart
P/BV x 2.8 8.4 33.3% View Chart
Dividend Yield % 0.6 0.7 78.8%  

Financials

 SUN PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
TORRENT PHARMA
Mar-19
SUN PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs6791,964 34.6%   
Low Rs3751,245 30.2%   
Sales per share (Unadj.) Rs121.1453.4 26.7%  
Earnings per share (Unadj.) Rs13.425.8 51.9%  
Cash flow per share (Unadj.) Rs20.762.3 33.2%  
Dividends per share (Unadj.) Rs2.7517.00 16.2%  
Dividend yield (eoy) %0.51.1 49.2%  
Book value per share (Unadj.) Rs172.6279.2 61.8%  
Shares outstanding (eoy) m2,399.26169.22 1,417.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.5 123.0%   
Avg P/E ratio x39.462.2 63.3%  
P/CF ratio (eoy) x25.525.8 98.9%  
Price / Book Value ratio x3.15.7 53.1%  
Dividend payout %20.665.9 31.2%   
Avg Mkt Cap Rs m1,264,650271,513 465.8%   
No. of employees `00017.513.6 128.7%   
Total wages/salary Rs m59,67114,038 425.1%   
Avg. sales/employee Rs Th16,608.15,642.6 294.3%   
Avg. wages/employee Rs Th3,409.61,032.4 330.3%   
Avg. net profit/employee Rs Th1,833.8320.9 571.5%   
INCOME DATA
Net Sales Rs m290,65976,728 378.8%  
Other income Rs m10,255571 1,797.5%   
Total revenues Rs m300,91477,299 389.3%   
Gross profit Rs m63,07619,831 318.1%  
Depreciation Rs m17,5336,177 283.8%   
Interest Rs m5,5535,038 110.2%   
Profit before tax Rs m50,2469,187 546.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,144-3,570 340.2%   
Tax Rs m6,0091,254 479.4%   
Profit after tax Rs m32,0934,363 735.6%  
Gross profit margin %21.725.8 84.0%  
Effective tax rate %12.013.6 87.6%   
Net profit margin %11.05.7 194.2%  
BALANCE SHEET DATA
Current assets Rs m310,69250,375 616.8%   
Current liabilities Rs m173,39651,653 335.7%   
Net working cap to sales %47.2-1.7 -2,836.4%  
Current ratio x1.81.0 183.7%  
Inventory Days Days9992 107.6%  
Debtors Days Days11268 163.4%  
Net fixed assets Rs m232,47783,648 277.9%   
Share capital Rs m2,399846 283.5%   
"Free" reserves Rs m411,69146,397 887.3%   
Net worth Rs m414,09147,244 876.5%   
Long term debt Rs m15,22639,129 38.9%   
Total assets Rs m646,938141,209 458.1%  
Interest coverage x10.02.8 355.9%   
Debt to equity ratio x00.8 4.4%  
Sales to assets ratio x0.40.5 82.7%   
Return on assets %5.86.7 87.4%  
Return on equity %7.89.2 83.9%  
Return on capital %10.212.3 82.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02522,103 298.7%   
Fx outflow Rs m38,6105,522 699.3%   
Net fx Rs m27,41516,581 165.3%   
CASH FLOW
From Operations Rs m21,96517,981 122.2%  
From Investments Rs m-6,813-2,413 282.3%  
From Financial Activity Rs m-27,305-13,145 207.7%  
Net Cashflow Rs m-8,4422,380 -354.7%  

Share Holding

Indian Promoters % 63.7 71.5 89.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 7.0 73.1%  
FIIs % 23.0 12.6 182.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 8.8 94.3%  
Shareholders   133,026 26,511 501.8%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 187 Points Higher(Closing)

Indian share markets end on a positive note with the Sensex up by 187 points, while the Nifty closed up by 36 points.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 7, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - BIOCON COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS